CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Clin Cancer Res
; 26(17): 4625-4632, 2020 09 01.
Article
in En
| MEDLINE
| ID: mdl-32209570
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
CA-125 Antigen
/
Drug Resistance, Neoplasm
/
Neoadjuvant Therapy
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: